Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis
- 9 December 1999
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 341 (24), 1795-1800
- https://doi.org/10.1056/nejm199912093412403
Abstract
There is no effective orally administered medication for any leishmania infection. We investigated miltefosine, which can be taken orally, for the treatment of Indian visceral leishmaniasis. Miltefosine is a phosphocholine analogue that affects cell-signaling pathways and membrane synthesis.Keywords
This publication has 19 references indexed in Scilit:
- Editorial Response: U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral LeishmaniasisClinical Infectious Diseases, 1999
- U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral LeishmaniasisClinical Infectious Diseases, 1999
- Inefficacy of Allopurinol as Monotherapy for Colombian Cutaneous LeishmaniasisAnnals of Internal Medicine, 1997
- Leishmaniasis: Public health aspects and controlClinics in Dermatology, 1996
- Treatment of kala-azar with oral fluconazoleThe Lancet, 1996
- Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in miceAntimicrobial Agents and Chemotherapy, 1992
- Ketoconazole in visceral leishmaniasisThe Lancet, 1990
- Ketoconazole in treatment of visceral leishmaniasisThe Lancet, 1990
- The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovaniBiochemical Pharmacology, 1987
- Activity of Oral Drugs against Leishmania Tropica in Human Macrophages in Vitro *The American Journal of Tropical Medicine and Hygiene, 1983